Serum folic acid: an effective indicator for arteriogenic erectile dysfunction.
arteriogenic erectile dysfunction
effective indicators
folic acid
peak systolic velocity
penile color Doppler ultrasonography
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
11
2022
accepted:
30
06
2023
medline:
10
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
The present study is the first to explore the correlation between serum folic acid (FA) level and penile arterial peak systolic velocity (PSV) as measured via penile color Doppler ultrasonography (PDU), which directly reflects endothelial function in the penile artery. A total of 244 consecutive erectile dysfunction (ED) patients and 72 healthy controls, recruited from the Andrology department and the Healthy Physical Examination Center of our hospital, respectively, from June 2020 to April 2022, were included in the study. Serum FA was measured in ED patients and healthy controls, and PDU examinations were conducted for all eligible ED patients. The Pearson method was used to evaluate the correlation between FA levels and PDU parameters in ED patients. A receiver operating characteristic (ROC) curve analysis was also performed to calculate the sensitivity and specificity of these parameters for prediction of arteriogenic ED. After the PDU test, the average serum FA level among patients diagnosed with arteriogenic ED was 8.08 ± 2.64 ng/ml, lower than the average of 10.78 ± 2.87 ng/ml among healthy controls. There were no statistically significant inter-group differences on any basic parameters, including age, body mass index, fasting blood glucose, total cholesterol, and triglyceride. For further analysis, we divided the arteriogenic ED group into three subgroups by PSV range to compare serum FA levels among these subgroups. The mean FA levels in each of these groups were 5.97 ± 1.51ng/ml, and 8.21 ± 2.37ng/ml, and 10.55 ± 2.56ng/ml, while the corresponding PSV values were 15.75 ± 2.39cm/s, 23.53 ± 2.19cm/s, and 32.72 ± 1.64cm/s. Overall, a positive correlation between PSV and FA level was found among patients with arteriogenic ED (r=0.605, P<0.001). Furthermore, when FA level was used, with a cut-off value of 10.045 ng/ml, as a criterion to distinguish patients with arteriogenic ED from healthy controls, the area under the curve (AUC) was 0.772 (95% confidential interval: [0.696, 0.848]), for a sensitivity of 0.611 and specificity of 0.824. Serum FA level is positively correlated with PSV in ED patients, and has the ability to distinguish patients with arteriogenic ED from healthy controls. Taking these findings together, FA deficiency should be regarded as an independent risk factor for arteriogenic ED.
Sections du résumé
Background
The present study is the first to explore the correlation between serum folic acid (FA) level and penile arterial peak systolic velocity (PSV) as measured via penile color Doppler ultrasonography (PDU), which directly reflects endothelial function in the penile artery.
Materials and methods
A total of 244 consecutive erectile dysfunction (ED) patients and 72 healthy controls, recruited from the Andrology department and the Healthy Physical Examination Center of our hospital, respectively, from June 2020 to April 2022, were included in the study. Serum FA was measured in ED patients and healthy controls, and PDU examinations were conducted for all eligible ED patients. The Pearson method was used to evaluate the correlation between FA levels and PDU parameters in ED patients. A receiver operating characteristic (ROC) curve analysis was also performed to calculate the sensitivity and specificity of these parameters for prediction of arteriogenic ED.
Results
After the PDU test, the average serum FA level among patients diagnosed with arteriogenic ED was 8.08 ± 2.64 ng/ml, lower than the average of 10.78 ± 2.87 ng/ml among healthy controls. There were no statistically significant inter-group differences on any basic parameters, including age, body mass index, fasting blood glucose, total cholesterol, and triglyceride. For further analysis, we divided the arteriogenic ED group into three subgroups by PSV range to compare serum FA levels among these subgroups. The mean FA levels in each of these groups were 5.97 ± 1.51ng/ml, and 8.21 ± 2.37ng/ml, and 10.55 ± 2.56ng/ml, while the corresponding PSV values were 15.75 ± 2.39cm/s, 23.53 ± 2.19cm/s, and 32.72 ± 1.64cm/s. Overall, a positive correlation between PSV and FA level was found among patients with arteriogenic ED (r=0.605, P<0.001). Furthermore, when FA level was used, with a cut-off value of 10.045 ng/ml, as a criterion to distinguish patients with arteriogenic ED from healthy controls, the area under the curve (AUC) was 0.772 (95% confidential interval: [0.696, 0.848]), for a sensitivity of 0.611 and specificity of 0.824.
Conclusion
Serum FA level is positively correlated with PSV in ED patients, and has the ability to distinguish patients with arteriogenic ED from healthy controls. Taking these findings together, FA deficiency should be regarded as an independent risk factor for arteriogenic ED.
Identifiants
pubmed: 37554765
doi: 10.3389/fendo.2023.1080188
pmc: PMC10405823
doi:
Substances chimiques
Folic Acid
935E97BOY8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080188Informations de copyright
Copyright © 2023 Feng, Mei, Xie, Xing, Wang, Cui and Xu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sex Med. 2021 Jun;9(3):100356
pubmed: 34051538
Radiology. 1985 Jun;155(3):777-81
pubmed: 3890009
Curr Heart Fail Rep. 2012 Sep;9(3):200-10
pubmed: 22711313
Circulation. 2018 Jul 31;138(5):540-542
pubmed: 29891569
Andrologia. 2017 Apr;49(3):
pubmed: 27421248
Curr Hypertens Rev. 2009 May 1;5(2):158-165
pubmed: 20495681
Am J Cardiol. 2005 Dec 26;96(12B):19M-23M
pubmed: 16387561
Circulation. 2013 Feb 12;127(6):749-56
pubmed: 23401116
Acta Biochim Pol. 2011;58(2):237-41
pubmed: 21681286
BJU Int. 1999 Jul;84(1):50-6
pubmed: 10444124
Can J Urol. 2014 Jun;21 Suppl 2:25-38
pubmed: 24978630
J Sex Med. 2010 Dec;7(12):3979-83
pubmed: 19912490
J Androl. 2003 Nov-Dec;24(6 Suppl):S17-37
pubmed: 14581492
Eur Urol. 2011 Jun;59(6):956-8
pubmed: 21333436
Andrology. 2019 Jan;7(1):82-87
pubmed: 30407754
Arch Ital Urol Androl. 2016 Oct 05;88(3):183-185
pubmed: 27711090
Asian J Androl. 2018 Sep 7;:
pubmed: 30198496
Curr Opin Cardiol. 2015 Jul;30(4):416-21
pubmed: 26049392
Andrologia. 2016 Jun;48(5):532-5
pubmed: 26302884
Am J Clin Nutr. 1992 Jan;55(1):131-8
pubmed: 1728812
J Sex Med. 2013 Apr;10(4):1146-50
pubmed: 23347176
J Sex Med. 2013 Jan;10(1):120-9
pubmed: 22970798
Atherosclerosis. 2005 Jul;181(1):159-65
pubmed: 15939068
Nutr Rev. 2017 Jan;75(1):61-70
pubmed: 27974600
Eur Urol. 2007 Dec;52(6):1590-600
pubmed: 17707576
Asian J Androl. 2014 Nov-Dec;16(6):902-6
pubmed: 25080932
J Sex Med. 2007 Sep;4(5):1437-47
pubmed: 17645448
Andrologia. 2021 Feb;53(1):e13890
pubmed: 33141950
Aging Male. 2018 Jun;21(2):116-120
pubmed: 29157083
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Urol. 1998 Jun;159(6):1921-6
pubmed: 9598488
BMJ Open. 2019 May 22;9(5):e023003
pubmed: 31122963
Cardiol Rev. 2011 Jan-Feb;19(1):5-11
pubmed: 21135596
Asian J Androl. 2018 Jul-Aug;20(4):400-404
pubmed: 29442076
Sex Med Rev. 2019 Jul;7(3):442-454
pubmed: 30612976
Eur Urol. 2006 Oct;50(4):721-31
pubmed: 16901623
Curr Atheroscler Rep. 2002 Sep;4(5):397-401
pubmed: 12162940
Eur Urol. 2014 May;65(5):979-80
pubmed: 24287318
J Am Chem Soc. 2010 Aug 25;132(33):11812-23
pubmed: 20669954
Eur Urol. 2014 Feb;65(2):455-64
pubmed: 24119319
BMJ. 2014 Jan 27;348:g129
pubmed: 24468580